The pedunculopontine nucleus (PPN) is a reticular nucleus located in the mesencephalic and upper pontine tegmentum. Initially, characterized by its predominant cholinergic projection neurons, it was associated with the "mesencephalic locomotor region" and "reticular activating system". Furthermore, based on histopathological studies, the PPN was hypothesized to play a role in the manifestation of symptoms in movement disorders such as Parkinson's disease (PD). Since axial symptoms represent unmet needs of PD treatments, a series of pioneering experiments in Parkinsonian monkeys promoted the idea of a potential new target for deep brain stimulation (DBS) and much clinical interest was generated in the following years leading to a number of trials analysing the role of PPN for gait disorders. This review summarizes the historical background and more recent findings about the anatomy and function of the PPN and its implications in the basal ganglia network of the normal as well as diseased brain. Classical views on PPN function shall be challenged by more recent findings. Additionally, the current role and future perspectives of PPN DBS in PD patients shall be outlined.
Introduction
Several independent findings based on animal models as well as in humans have indicated a role of the pedunculopontine nucleus (PPN) in motor function over the past few decades. The PPN is located in the mesencephalic and upper pontine tegmentum and was classically identified by its predominant cholinergic neurons. Based on its widespread connections to other areas of the brain and spinal cord, the PPN is involved in a variety of functions. Most importantly with regard to clinical implications, altered PPN function in a parkinsonian model of non-human primates promoted the idea of this nucleus to be a possible new target for treating motor symptoms in Parkinson's disease (PD) as early as 1989 (Mitchell et al., 1989) . Consecutive primate studies supported the concept that PPN plays a crucial role in motor function. Particularly, high-frequency stimulation of the PPN was reported to reduce motor activity in the intact non-human monkey and low-frequency PPN-DBS could successfully improve motor activity in a primate model of PD (Jenkinson et al., 2004; Nandi et al., 2002b) . Based on these and other pioneering findings, the PPN was targeted in humans in order to treat predominantly gait disturbances associated with Parkinson's disease or other movement disorders (Pereira et al., 2008; Stefani et al., 2007) . However, initial enthusiasm about this promising new target was dampened by mixed outcome results of PPN DBS reported by different centers in the course of the following years (Hamani et al., 2011) . Parallel to clinical studies analysing the effect of PPN-DBS, a tremendous number of animal studies has refined our understanding of the PPN and its involvement in many neurophysiological processes beyond motor function such as regulation of the sleep-wake-cycle, involvement in reward circuits and influence of behavioural decisionmaking (Mena-Segovia and Bolam, 2017; Winn, 2006) . This review article aims to give a brief historical background and to report on more recent findings about the anatomy and function of the PPN and its implications in the basal ganglia network of the normal as well as diseased brain. Furthermore, the current and future role of PPN-DBS in humans shall be discussed.
Anatomical considerations
The PPN is an evolutionary highly conserved structure which is found in almost every species that has so far been studied including fish, amphibians and vertebrates (Brantley and Bass, 1988; Honda and Semba, 1995; Marin et al., 1997; Rye et al., 1987 
